Form 4: Teva Executive Matthew Shields Reports Vesting of Restricted Share Units and Tax-Related Share Sale

Teva Pharmaceutical Industries Ltd.'s EVP of Global Operations, Matthew Shields, reported the vesting of 16,195 restricted share units and a subsequent sale of 6,206 ordinary shares to cover tax obligations.

Summary

• Matthew Shields, Teva Pharmaceutical Industries Ltd.'s Executive Vice President of Global Operations, reported transactions on June 3, 2025, related to his equity compensation.
• 16,195 Restricted Share Units (RSUs) held by Mr. Shields vested on June 3, 2025, resulting in the acquisition of 16,195 ordinary shares.
• Concurrently, Mr. Shields disposed of 6,206 ordinary shares at a price of $17.0203 per share to satisfy tax withholding obligations associated with the RSU vesting.
• Following these transactions, Mr. Shields directly beneficially owns 9,989 ordinary shares.
• He also continues to hold 48,587 unvested Restricted Share Units, with future vesting scheduled for June 3, 2026 (16,195 units), June 3, 2027 (16,195 units), and June 3, 2028 (16,197 units).

Sentiment

Score: 7

Explanation: The filing reports a routine vesting of restricted share units and a subsequent tax-related sale, which is a standard part of executive compensation and does not indicate any negative operational or financial issues for the company. The executive retains a significant number of shares and unvested units, suggesting continued alignment.

Positives

• The vesting of Restricted Share Units represents a planned component of executive compensation, aligning management's interests with shareholder value over time.
• The executive continues to hold a significant number of unvested RSUs, indicating a long-term commitment to the company's performance.

Negatives

• The sale of 6,206 ordinary shares, while for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

The document indicates a continued long-term incentive alignment for the executive through scheduled future vesting of remaining Restricted Share Units on June 3, 2026, June 3, 2027, and June 3, 2028.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of equity awards and a subsequent tax-related share sale. Such transactions are common across industries, including pharmaceuticals, as a standard component of long-term incentive plans for executives.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity ownership and compensation practices, which is a standard disclosure for publicly traded companies.
• Employees: Reflects the company's standard executive compensation practices, which often include equity-based incentives.

Next Steps

• Future vesting of remaining restricted share units on June 3, 2026, June 3, 2027, and June 3, 2028.

Key Dates

Recommendation

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Share Sale, Executive Compensation, Matthew Shields, Pharmaceuticals